MEDICLIN AG (MED.DE) Fundamental Analysis & Valuation

FRA:MED • DE0006595101

Current stock price

3.6 EUR
+0.18 (+5.26%)
Last:

This MED.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. MED.DE Profitability Analysis

1.1 Basic Checks

  • In the past year MED was profitable.
  • MED had a positive operating cash flow in the past year.
  • In multiple years MED reported negative net income over the last 5 years.
  • In the past 5 years MED always reported a positive cash flow from operatings.
MED.DE Yearly Net Income VS EBIT VS OCF VS FCFMED.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 3.85%, MED is in the better half of the industry, outperforming 78.79% of the companies in the same industry.
  • MED has a Return On Equity of 14.15%. This is amongst the best in the industry. MED outperforms 84.85% of its industry peers.
  • With a decent Return On Invested Capital value of 7.06%, MED is doing good in the industry, outperforming 75.76% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for MED is below the industry average of 6.06%.
  • The 3 year average ROIC (3.46%) for MED is below the current ROIC(7.06%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.85%
ROE 14.15%
ROIC 7.06%
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
MED.DE Yearly ROA, ROE, ROICMED.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10

1.3 Margins

  • MED's Profit Margin of 4.40% is fine compared to the rest of the industry. MED outperforms 69.70% of its industry peers.
  • In the last couple of years the Profit Margin of MED has grown nicely.
  • MED's Operating Margin of 8.52% is fine compared to the rest of the industry. MED outperforms 66.67% of its industry peers.
  • MED's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 84.08%, MED belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
  • MED's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.52%
PM (TTM) 4.4%
GM 84.08%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
MED.DE Yearly Profit, Operating, Gross MarginsMED.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. MED.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MED is creating some value.
  • Compared to 1 year ago, MED has about the same amount of shares outstanding.
  • MED has about the same amout of shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MED has been reduced compared to a year ago.
MED.DE Yearly Shares OutstandingMED.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MED.DE Yearly Total Debt VS Total AssetsMED.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 1.58, we must say that MED is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.58, MED is in line with its industry, outperforming 42.42% of the companies in the same industry.
  • MED has a debt to FCF ratio of 9.63. This is a negative value and a sign of low solvency as MED would need 9.63 years to pay back of all of its debts.
  • MED has a Debt to FCF ratio of 9.63. This is comparable to the rest of the industry: MED outperforms 54.55% of its industry peers.
  • MED has a Debt/Equity ratio of 1.69. This is a high value indicating a heavy dependency on external financing.
  • MED's Debt to Equity ratio of 1.69 is on the low side compared to the rest of the industry. MED is outperformed by 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF 9.63
Altman-Z 1.58
ROIC/WACC1.49
WACC4.73%
MED.DE Yearly LT Debt VS Equity VS FCFMED.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.93 indicates that MED should not have too much problems paying its short term obligations.
  • MED's Current ratio of 1.93 is amongst the best of the industry. MED outperforms 87.88% of its industry peers.
  • MED has a Quick Ratio of 1.89. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
  • MED's Quick ratio of 1.89 is amongst the best of the industry. MED outperforms 90.91% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.89
MED.DE Yearly Current Assets VS Current LiabilitesMED.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. MED.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 414.18% over the past year.
  • The Earnings Per Share has been growing by 20.79% on average over the past years. This is a very strong growth
  • MED shows a small growth in Revenue. In the last year, the Revenue has grown by 3.40%.
  • MED shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.19% yearly.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%

3.2 Future

  • Based on estimates for the next years, MED will show a very strong growth in Earnings Per Share. The EPS will grow by 22.30% on average per year.
  • Based on estimates for the next years, MED will show a small growth in Revenue. The Revenue will grow by 3.41% on average per year.
EPS Next Y78.05%
EPS Next 2Y34.35%
EPS Next 3Y22.3%
EPS Next 5YN/A
Revenue Next Year5.81%
Revenue Next 2Y4.12%
Revenue Next 3Y3.41%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MED.DE Yearly Revenue VS EstimatesMED.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
MED.DE Yearly EPS VS EstimatesMED.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

9

4. MED.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 4.86, the valuation of MED can be described as very cheap.
  • Based on the Price/Earnings ratio, MED is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 25.70, MED is valued rather cheaply.
  • MED is valuated cheaply with a Price/Forward Earnings ratio of 4.82.
  • 100.00% of the companies in the same industry are more expensive than MED, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.84, MED is valued rather cheaply.
Industry RankSector Rank
PE 4.86
Fwd PE 4.82
MED.DE Price Earnings VS Forward Price EarningsMED.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MED is valued cheaper than 93.94% of the companies in the same industry.
  • 90.91% of the companies in the same industry are more expensive than MED, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 3.68
EV/EBITDA 2.76
MED.DE Per share dataMED.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • MED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MED may justify a higher PE ratio.
  • A more expensive valuation may be justified as MED's earnings are expected to grow with 22.30% in the coming years.
PEG (NY)0.06
PEG (5Y)0.23
EPS Next 2Y34.35%
EPS Next 3Y22.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. MED.DE Dividend Analysis

5.1 Amount

  • MED has a Yearly Dividend Yield of 1.17%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 1.63, MED has a dividend in line with its industry peers.
  • MED's Dividend Yield is slightly below the S&P500 average, which is at 1.89.
Industry RankSector Rank
Dividend Yield 1.17%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MED.DE Yearly Dividends per shareMED.DE Yearly Dividends per shareYearly Dividends per share 2019 2025 0.01 0.02 0.03 0.04

5.3 Sustainability

DPN/A
EPS Next 2Y34.35%
EPS Next 3Y22.3%
MED.DE Yearly Income VS Free CF VS DividendMED.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

More info and screens

Find the best dividend stocksShow peers with best dividend

MED.DE Fundamentals: All Metrics, Ratios and Statistics

MEDICLIN AG

FRA:MED (3/13/2026, 7:00:00 PM)

3.6

+0.18 (+5.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04
Earnings (Next)03-26
Inst Owners0.8%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap171.00M
Revenue(TTM)797.34M
Net Income(TTM)35.05M
Analysts80
Price Target5.87 (63.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.17%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)9.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.72%
Revenue NY rev (3m)0.72%
Valuation
Industry RankSector Rank
PE 4.86
Fwd PE 4.82
P/S 0.21
P/FCF 3.68
P/OCF 1.77
P/B 0.69
P/tB 0.77
EV/EBITDA 2.76
EPS(TTM)0.74
EY20.56%
EPS(NY)0.75
Fwd EY20.76%
FCF(TTM)0.98
FCFY27.19%
OCF(TTM)2.04
OCFY56.53%
SpS16.79
BVpS5.21
TBVpS4.7
PEG (NY)0.06
PEG (5Y)0.23
Graham Number9.32
Profitability
Industry RankSector Rank
ROA 3.85%
ROE 14.15%
ROCE 9.1%
ROIC 7.06%
ROICexc 9.61%
ROICexgc 10.05%
OM 8.52%
PM (TTM) 4.4%
GM 84.08%
FCFM 5.83%
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF 9.63
Debt/EBITDA 3.49
Cap/Depr 96.09%
Cap/Sales 6.29%
Interest Coverage 3.18
Cash Conversion 80.47%
Profit Quality 132.66%
Current Ratio 1.93
Quick Ratio 1.89
Altman-Z 1.58
F-Score8
WACC4.73%
ROIC/WACC1.49
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
EPS Next Y78.05%
EPS Next 2Y34.35%
EPS Next 3Y22.3%
EPS Next 5YN/A
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
Revenue Next Year5.81%
Revenue Next 2Y4.12%
Revenue Next 3Y3.41%
Revenue Next 5YN/A
EBIT growth 1Y281.51%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year143.72%
EBIT Next 3Y33.62%
EBIT Next 5YN/A
FCF growth 1Y196.83%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.85%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%

MEDICLIN AG / MED.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.


Can you provide the valuation status for MEDICLIN AG?

ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.


Can you provide the profitability details for MEDICLIN AG?

MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for MED stock?

The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 4.86 and the Price/Book (PB) ratio is 0.69.


What is the financial health of MEDICLIN AG (MED.DE) stock?

The financial health rating of MEDICLIN AG (MED.DE) is 4 / 10.